Cvs Health

CVS Healthcare & Pharma 4/10 Medium Risk
4/10
Sector avg: 2.8/10

Cvs Health has $63.7B in scheduled debt maturities. CVS shows thin interest coverage of 1.8x. DebtCanary scores CVS at 4/10, indicating moderate refinancing pressure.

Maturity Schedule

Year 1 $4.0B Year 2 $3.4B Year 3 $5.0B Year 4 $3.8B Year 5 $4.3B Beyond 5 $43.3B
Period Amount Due % of Total
Year 1 (0-12 months) $4.0B 6.3%
Year 2 (12-24 months) $3.4B 5.3%
Year 3 (24-36 months) $5.0B 7.9%
Year 4 (36-48 months) $3.8B 5.9%
Year 5 (48-60 months) $4.3B 6.7%
Beyond 5 Years $43.3B 68.0%
Total Scheduled Maturities $63.7B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$4.0B
Interest Coverage
1.8x
Debt/Equity
0.85
Cash Coverage
2.11x
Operating Income
$4.7B
EBITDA
$9.3B
Debt / EBITDA
6.9x
EBITDA / Interest
3.5x

Score Components

Component Value Weight
Near-Term Maturity Concentration 6.3% 30%
Interest Coverage Ratio 1.8x 25%
Debt-to-Equity Ratio 0.85 25%
Cash Coverage of Near-Term Debt 2.11x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-10. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.
View SEC EDGAR filings for Cvs Health →